Melanotan II

This is the foundational design paper describing the rational, computationally-guided construction of a cyclic lactam class of α-melanotropin analogs at the University of Arizona. Using quenched dynamic simulations to identify a low-energy conformation of the α-MSH message sequence, the authors designed a series of side-chain-to-side-chain lactam-bridged heptapeptides — including the compound that became known as Melanotan-II — in which Asp and Lys residues are covalently linked to constrain the backbone. In the classical frog skin (Rana pipiens) and lizard skin (Anolis carolinensis) melanocyte bioassays, the cyclic lactam analogs displayed melanotropic potencies several orders of magnitude greater than native α-MSH, with prolonged biological activity attributed to resistance to enzymatic degradation. The work established the structural template for the entire downstream class of cyclic melanocortin agonists, including PT-141 (bremelanotide) and afamelanotide.

Scientists at the University of Arizona used computer simulations to figure out the best three-dimensional shape for a melanocortin-stimulating molecule, then built that shape into a small ring-shaped peptide. The ring locks the molecule into a single active conformation and protects it from being broken down by enzymes. In frog and lizard skin tests — standard tools for measuring melanocyte activity at the time — the resulting compound, Melanotan-II, was hundreds to thousands of times more active than the body's natural α-MSH. This paper is the chemistry blueprint that every later melanocortin compound, including the FDA-approved bremelanotide, was built on.

This pilot phase-I trial — conducted at the University of Arizona by the same group that designed the molecule — evaluated subcutaneous MT-II in three healthy adult male volunteers under a single-blind, placebo-alternating protocol at a starting dose of 0.01 mg/kg administered Monday through Friday for two consecutive weeks. Quantitative reflectance measurements and visual scoring documented increased pigmentation of facial, upper-body, and gluteal skin in two of three subjects, persisting one week after the dosing period ended. The investigators recorded dose-related nausea, facial flushing, and spontaneous penile erections as the principal adverse events, with the erectogenic effect appearing 1–5 hours post-injection and correlating with a stretching-and-yawning complex. This paper is the most-cited primary human pharmacology source for MT-II and is the observation that directly motivated the spin-off development of bremelanotide (PT-141) as a melanocortin-targeted compound for sexual response research.

The Arizona team gave low subcutaneous doses of MT-II to three healthy adult volunteers over two weeks and measured what happened. Skin in sun-exposed and non-sun-exposed areas got measurably darker in two of the three subjects, and the effect outlasted the dosing period by at least a week. The investigators also noted, unexpectedly, that MT-II produced spontaneous erections in the male volunteers — an observation that surprised the team and eventually led another group to develop PT-141 (bremelanotide), a closely related molecule, as a separate research compound focused on the sexual-response side of melanocortin pharmacology rather than on pigmentation.